| About bladder cancer |
|
|
|
|
See also: The American Cancer Society estimates that 2006 will see 61,420 new cases of bladder cancer diagnosed in the United States, with approximately 13,060 deaths. There are currently 600,000 bladder cancer survivors in the U.S. Worldwide, bladder cancer is the 4th most frequent solid tumor in men and the 7th in women, with more than 350,000 new cases diagnosed worldwide every year.1 Thanks in large part to its good long term survival rates, bladder cancer is one of the most prevalent cancers, surpassing lung cancer survivors in number, as well as one of the most expensive cancers for the health industry. The recurrence rate for bladder cancer is 80 percent; it is estimated that nearly 400,000 individuals in the United States are at risk for recurrence.2 The chief symptom of bladder cancer is hematuria, or blood in the urine. All people who have visible blood in the urine should be considered to have bladder cancer until proven otherwise. Because hematuria can come and go, a negative result on urinalysis cannot exclude the diagnosis of bladder cancer.3 Bladder cancer is steadily increasing. The projected rise is 28% by 2010 for both men and women. Bladder cancer is one of the most preventable cancers; Smoking is the greatest risk factor for bladder cancer, with smokers experiencing twice the risk of nonsmokers for developing the disease. Individuals living in urban areas -especially the American northeast - and those working in the dye, rubber, or leather industries are also at a higher risk. Because bladder cancer most often occurs in people over age 60, a major determinant of the future cancer burden is the aging of baby-boomers and increasing size of the U.S. population. The total number of cancer cases can be expected to double by 2050 if current incidence rates remain stable (source: American Cancer Society).
Women and African Americans - higher mortality
A greater proportion of Afro-Americans present with aggressive tumor types
associated with poorer survival. Among those with pure urothelial carcinoma,
black patients had greater extent of disease at the time of diagnosis.
Within specific extent-of-disease categories, there was some evidence
of poorer survival for black patients with T2 tumors and strong evidence
of poorer survival among those with T3 tumors compared with white patients.
Black patients with muscle-invasive carcinoma who died within 6 months
of diagnosis tended to present with life-threatening symptoms. Black patients
and white patients did not differ with respect to diagnostic tests performed
or therapy given. 5 See also: Racial Disparities:Article from NCI
About 20% have muscle-invasive disease (stages T2-T4), while 80% present first with superficial (Ta - T1) tumours. Stage Ta tumors are high grade (aggressive) in only 1% to 3% of cases. Most often, they are low to moderate grade. In contrast, stage T1 tumors may be high grade in 30% to 50% of cases and are rarely low grade.7 See also; staging Over 90% of bladder cancers in westernized, industrial countries are Transitional Cell Carcinomas, so called because these cells have the capability to undergo changes in size from cubical (when the bladder is empty) to flat (when the bladder is full). TCC that originates in the kidneys or ureters, know as upper tract TCC, is a rare-5%-but aggressive form of cancer.8 Carcinoma in situ will comprise approximately 10% of TCC diagnoses.
For information on rare cell types that may present in the bladder, see this page: Rare Types for more information on:
For a photograph of a low grade papillary tumor of 2 cm, see ### LINK NOT FOUD ###Art's
'picture of my bladder tumor' .
References
|
|
| Last Updated ( Friday, 14 March 2008 ) |



